Image credit: Canva
Lung cancer is one of the most common cancer types in the United States; non-small cell lung cancer, a prevalent subtype, can be hard to treat and is often fatal. Researchers want to know if treating bacteria in the lungs can help. A clinical trial led by Chen Zhao, M.D., Stadtman Investigator in the Thoracic and GI Malignancies Branch, is researching a combination therapy for non-small cell lung cancer.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, contact Shannon Swift at (240) 858-3157 or shannon.swift@nih.gov.
Clinicaltrials.gov identifier: NCT05777603
NCI Protocol ID: IRB001516
Official Title: Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.